Monday 24 Jun, 2024 11:11 AM
Site map | Locate Us | Login
   Lupin gains on receiving EIR from USFDA for New Jersey facility    MAS Financial gains on raising Rs 500 crore via QIP    Welspun Specialty spurts after emerging as L1 bidder for thermal power project    Capital Goods shares gain    Consumer Durables shares rise    FMCG shares gain    Cipla slides as Goa facility gets 6 USFDA observations    RVNL hits life high on emerging as L-1 bidder for Rs 191-cr railway project    Biocon's new monoclonal antibodies facility in India get manufacturing approval from EMA    Sky Gold hits record high on acquiring Starmangalsutra & Sparkling Chains    DLF Ltd Slides 2.1%, BSE Realty index Shed 1.28%    Bombay Burmah Trading Corporation Ltd Spurts 3.57%    Garden Reach bags contract from German company for construction of multi-purpose vessels    Inox Green Energy board OKs fund raising proposal    Cipla Goa facility gets 6 USFDA observations 
Saravan Stocks
       
Hot Pursuit
Scrips, which has significant changes during the market hours.
Strides Pharma hits 52-week high on reporting turnaround Q4 performance
22-May-24   15:14 Hrs IST

The company reported highest ever quarterly revenue of Rs 1,058.3 crore in Q4 FY24, registering a growth of 6.9% from Rs 990.4 crore recorded in Q4 FY23.

Profit before exceptional items and tax was at Rs 86.27 crore in Q4 FY24, up 109.24% from Rs 41.23 crore recorded in Q4 FY23. The company reported an exceptional loss of Rs 8.07 crore during the quarter.

The firm reported highest ever quarterly EBITDA of Rs 204 crore in Q4 FY24, registering a growth of 27.82% year on year. EBITDA margin improved to 19.3% in Q4 FY24 as compared to 16.1% recorded in the corresponding quarter previous year.

Gross margin rose 8.9% YoY to Rs 642.1 crore during the quarter. Gross margin returned to a historic high of 60.7% in Q4 FY24.

The US business achieved revenue of $65 million in Q4 FY24, up 5.5% on YoY basis.

For FY24, the pharma company's consolidated net loss narrowed to Rs 148.53 crore in FY24 as against Rs 230.90 crore posted in FY23. The company reported sales of Rs 4,055.5 crore in FY24, registering a growth of 14.4% YoY.

Arun Kumar, founder, executive chairperson & managing director, commented, ?The company achieved all its key objectives laid down in our reset strategy and has bounced back to become a strong and resilient company. In the near term, we will continue to focus on operating cash flows while investing in growth to ensure that the efforts of our Reset are balanced by improved revenue CAGR, in the coming years.

Meanwhile, the company's board has recommended a final dividend of Rs 2.50 per equity share for FY24. The dividend will be paid within 30 days from the date of shareholders' approval at the ensuing AGM of the company.

Further, the pharma company announced that its step-down wholly owned subsidiary, Strides Pharma Global, has received approval for the generic version of Sucralfate Oral Suspension from the United States Food & Drug Administration (USFDA).

The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Carafate of AbbVie.

Sucralfate is used to treat stomach ulcers, gastroesophageal reflux disease (GERD), radiation proctitis, and stomach inflammation and to prevent stress ulcers.

As per IQVIA March 2024 data, Sucralfate Oral Suspension has a market size of of around $124 million. The said drug will be manufactured at the company?s flagship facility in KRS Gardens in Bangalore, India.

The company has 260 cumulative ANDA filings (including the acquired portfolio from Endo at Chestnut Ridge) with USFDA, of which over 245 ANDAs have been approved. The company has set a target to launch 60 new products over three years in the US, stated in the company?s press release.

Strides Pharma Science is engaged in develops and manufactures a wide range of IP-led niche pharmaceutical products.

The scrip hit 52-week high at Rs 919.35 in today?s intraday session.

Powered by Capital Market - Live News

   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.R Udayakumar , compliance@ssplwealth.com,  Mobile No: 7305522205
Hit Count : 33424790
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 56990 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. SSPL WEALTH Pvt. Ltd